๐ฐ Thyroid Nodules News
Page 2 - Thyroid Nodules News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thyroid Nodules. Real-time updates on events, politics, business and more.
June 11, 2022
Artificial intelligence (AI) pinpoints thyroid nodules noticed on thyroid ultrasound that are unlikely to be cancerous.
February 17, 2022
/PRNewswire/ -- Allied Market Research recently published a report, titled, "Thyroid Ablation Devices Market by Type (Image-guided Ablation, Radiofrequency...
February 17, 2022
Rise in prevalence of thyroid cancer and thyroid nodules and demand for minimally invasive procedures, drive the growth of the global thyroid ablation devices market. PORTLAND, Ore., Feb.
February 17, 2022
/PRNewswire/ -- Allied Market Research recently published a report, titled, "Thyroid Ablation Devices Market by Type (Image-guided Ablation, Radiofrequency...
June 2, 2021
The LUCA device shows high accuracy in thyroid cancer screening Thyroid nodules are a common pathology having a prevalence of 19-76% when screened with ultrasound, with higher frequencies in women. Current medical methods used to assess the malignancy of a nodule consist in performing an ultrasound, followed by a Doppler ultrasound, and then a biopsy. However, unfortunately, these methods present both low specificity and low sensitivity. This insufficient effectiveness in accurately being able ...
June 1, 2021
ย E-Mail IMAGE:ย First lab tests in 2019 of the LUCA device at ICFO research center in Barcelona. Dr. Mattia Squarcia tests the probe on a healthy patient to see the performance of... view moreย Credit: ICFO Thyroid nodules are a common pathology having a prevalence of 19-76% when screened with ultrasound, with higher frequencies in women. Current medical methods used to assess the malignancy of a nodule consist in performing an ultrasound, followed by a Doppler ultrasound, and then a b...
December 21, 2020
Published: Dec 21, 2020 ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX ยฎ) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies, met the co-primary endpoint of demonstrating significant improvement in progression-free survival. Cabozantin...
September 16, 2012
Do that? >> it is point for doctors to be involved, if your doctors thinks so -- and the dha an epa, that is what is in fish and know the good stuff is in the fatty fish we are talking about and the salmon and mackerel and the sardines, you get the good stuff there. >> jamie: always better in food. >> if possible. >> eric: especially it is grilled. and, people diagnosed with thyroid disease, they say 27 million americans have thyroid disease, and, 13 million are undiagnosed. dr. samadi, how do y...